| Literature DB >> 33764148 |
Shelley L Wall1, Nikki L Allorto, Verusia Chetty.
Abstract
BACKGROUND: Despite the exceptional burden of burns in low- and middle-income countries (LMIC) and the importance of adequate analgesia in burn care, there is a lack of analgesia protocol developed in resource-scarce settings. This necessitates the development of an analgesia protocol applicable to the resource-scarce setting. This study presents the findings of a modified Delphi study aimed at achieving consensus by a panel of experts in the management of burn injuries from low- and middle-income settings across Africa.Entities:
Keywords: LMIC’s; analgesia protocol; burns; low- and middle-income countries; paediatrics; resource-limited
Mesh:
Substances:
Year: 2021 PMID: 33764148 PMCID: PMC8378142 DOI: 10.4102/safp.v63i1.5193
Source DB: PubMed Journal: S Afr Fam Pract (2004) ISSN: 2078-6190
FIGURE 1Overview of the Delphi process.
A summary of the consensus for each of the drug items across the two rounds.
| Variable | Round 1 ( | Round 2 ( | ||||||
|---|---|---|---|---|---|---|---|---|
| Essential/useful (of those who responded) | Unnecessary/unsure (of those who responded) | Essential/useful | Unnecessary | |||||
|
| % |
| % |
| % |
| % | |
|
| ||||||||
|
| ||||||||
| Paracetamol 15 mg/kg 6-hourly | 9/9 | 100.0 | - | 0.0 | - | - | - | - |
|
| ||||||||
| Tilidine 1 mg/kg 6-hourly | 4/8 | 50.0 | 4/8 | 50.0 | 6/8 | 75.0 | 2/8 | 25.0 |
|
| ||||||||
| Ibuprofen 10 mg/kg 8-hourly | 8/8 | 100.0 | - | 0.0 | - | - | - | - |
| Consider contraindications of Ibuprofen: Curling’s ulcer, acute kidney injury and comorbidities | 4/4 | 100.0 | - | 0.0 | 9/9 | 100.0 | - | 0.0 |
|
| ||||||||
| Morphine syrup: Start at 0.2 mg/kg 6-hourly. Increase frequency up to 2-hourly then increase dose by 25%. Consider an infusion. | 9/9 | 100.0 | - | 0.0 | - | - | - | - |
|
| ||||||||
| Clonidine 25 mcg 8- hourly. Increase to maximum 50 mcg 8-hourly | 8/9 | 88.9 | 1/9 | 11.1 | - | - | - | - |
|
| ||||||||
| Pregabalin start at 25 mg 12-hourly. Increase in 25 mg increments to max 75 mg 12-hourly | 6/6 | 100.0 | - | 0.0 | 8/8 | 100.0 | - | 0.0 |
| Gabapentin 10 mg/kg 8-hourly. Increase in increments of 100 mg/dose up to 600 mg 8-hourly | 6/6 | 100.0 | - | 0.0 | 8/8 | 100.0 | - | 0.0 |
|
| ||||||||
| Allergex 0.1 mg/kg. Start 12-hourly, can be increased to 8-hourly | 7/8 | 87.5 | 1/8 | 12.5 | 7/8 | 87.5 | 1/8 | 12.5 |
|
| ||||||||
| Morphine IVI 0.1 mg/kg loading dose, then 0.1 mg/kg/h infusion Increase to effect, reload and increase rate by 0.05 mg/kg | 8/8 | 100.0 | - | 0.0 | - | - | - | - |
|
| ||||||||
| Valium 2.5 mg nocte, titrate to effect. Can be increased to 8-hourly | 5/7 | 71.4 | 2/7 | 28.6 | 7/8 | 87.5 | 1/8 | 12.5 |
|
| ||||||||
|
| ||||||||
| Ketamine 1 mg/kg IVI titrations. Quick onset, quick offset | 9/9 | 100.0 | - | 0.0 | - | - | - | - |
|
| ||||||||
| Ketamine 5 mg/kg per os | 9/9 | 100.0 | - | 0.0 | - | - | - | - |
|
| ||||||||
| Ketamine. Half the previous ketamine dose given IMI. 5–10 mins onset. | 6/9 | 66.7 | 3/9 | 33.3 | 7/8 | 87.5 | 1/8 | 12.5 |
|
| ||||||||
| Ketamine half the previous ketamine dose IMI | 6/8 | 75.0 | 2/8 | 25.0 | 8/8 | 100.0 | - | 0.0 |
| The final total dose of ketamine given at the procedure must be written as the script for the following dressing change. Do not leave the inadequate dose as the prescription | 1/1 | 100.0 | - | 0.0 | 8/8 | 100.0 | - | 0.0 |
|
| ||||||||
| Ketamine 5 mg/kg IMI | 6/7 | 85.7 | 1/7 | 14.3 | 7/8 | 87.5 | 1/8 | 12.5 |
|
| ||||||||
| Ketamine 5 mg/kg IMI | 9/9 | 100.0 | - | 0.0 | - | - | - | - |
TBSA, total body surface area; PTSD, post-traumatic stress disorder; IMI, intra-muscular injection; per os, per mouth.
Demographics.
| Variable | Round 1 ( | Round 2 ( |
|---|---|---|
|
| ||
| Male | 100.0% | 100.0% |
|
| ||
| 31–40 | 11.1% | 12.50% |
| 41–50 | 22.2% | 12.50% |
| 51–60 | 44.4% | 50% |
| > 60 | 22.2% | 25% |
|
| ||
| Plastic surgeon | 44.4% | 37.50% |
| General surgeon | 33.3% | 37.50% |
| Anaesthetist | 11.1% | 12.50% |
| Paediatric surgeon | 11.1% | 12.50% |
|
| ||
| 11–15 | 11.1% | 12.50% |
| 16–20 | 11.1% | 12.50% |
| > 20 | 77.8% | 75% |
|
| ||
| 6–10 | 11.1% | 12.50% |
| 11–15 | 11.1% | 12.50% |
| 16–20 | 22.2% | 12.50% |
| > 20 | 55.6% | 62.50% |